ArticleBiodegradation2025
Enhanced biodegradation of fluorinated pharmaceutical by Aspergillus flavus and Cunninghamella elegans biofilms: kinetics and mechanisms.
Article in Biodegradation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increasing occurrence of pharmaceutical compounds in aquatic environments poses significant ecological and public health challenges due to the persistence and bioaccumulation potential. While Aspergillus flavus and Cunninghamella elegans have demonstrated efficacy in removing heavy metals and dyes, their potential for pharmaceutical bioremediation remains unexplored. This study investigated these fungi capacity to degrade three persistent fluorinated pharmaceutical-atorvastatin (ATO), ciprofloxacin (CIP), and fluoxetine (FLX), through an innovative biofilm-based approach. Using polyurethane foam (PUF) as a carrier in two different configurations (fixed foam (PUF-F) and moving foam (PUF-M)), the performance of both fungal species was evaluated. C. elegans biofilms on PUF-F demonstrated high removal efficiencies of 97.3% for ATO and 97.7% for CIP, while A. flavus achieved 92.4% FLX reduction in the same system. Notably, the biofilm-based systems consistently outperformed carrier-free cultures, confirming the advantage of immobilized fungal growth. Kinetic analysis indicated pseudo-first-order degradation with remarkably short half-lives (1.0-1.7 days), surpassing reported values for white-rot fungi. Although adsorption contributed minimally (< 10%) to overall removal, species-specific biofilm characteristics emerged as key factors: C. elegans exhibited superior surface hydrophobicity (0.76) and stress resistance, whereas A. flavus developed denser extracellular matrices. These findings highlight the potential of tailored fungal biofilm systems for efficient removal of recalcitrant pharmaceutical, presenting a promising biological solution for wastewater treatment applications. The study provides critical insights into species-specific degradation mechanisms and operational parameters that could guide the development of scalable fungal bioremediation technologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.